P/E ratio for Vanda Pharmaceuticals (VNDA)
P/E ratio as of May 2024 (TTM): 19.0
According to Vanda Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19. At the end of 2022 the company had a P/E ratio of 61.6.
P/E ratio history for Vanda Pharmaceuticals from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 61.6 | 135.5% |
| 2021 | 26.2 | -14.43% |
| 2020 | 30.6 | 304.09% |
| 2019 | 7.56 | -85.53% |
| 2018 | 52.3 | -216.9% |
| 2017 | -44.7 | 17.72% |
| 2016 | -38.0 | 283.43% |
| 2015 | -9.90 | -126.28% |
| 2014 | 37.7 | -303.45% |
| 2013 | -18.5 | 390.59% |
| 2012 | -3.78 | -71.45% |
| 2011 | -13.2 | -136.34% |
| 2010 | 36.4 | -526.91% |
| 2009 | -8.52 | 3189.77% |
| 2008 | -0.2591 | -89.42% |
| 2007 | -2.45 | 3749.1% |
| 2006 | -0.0636 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.7 | -43.43% | 🇺🇸 USA |
 Novartis NVS | 27.6 | 45.38% | 🇨🇭 Switzerland |
 Pfizer PFE | 15.3 | -19.69% | 🇺🇸 USA |
 Eli Lilly LLY | 141 | 640.61% | 🇺🇸 USA |
 Merck MRK | 70.6 | 271.72% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -40.73% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | -11.5 | -160.59% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.